Celularity
Celularity is a clinical-stage biotechnology company developing placental-derived allogeneic cell therapies and regenerative-medicine products, including the Cenplacel-L point-of-care cellular therapeutic being deployed in regenerative-medicine programs and a portfolio of natural-killer (NK) and T-cell oncology candidates. The company received a Nasdaq notice in May 2026 for delayed filing of its Q1 2026 Form 10-Q and is operating under a 60-day cure-plan window from that notice. Celularity completed a $30M NexGel biomaterials out-license in June 2026 alongside new product-availability partnerships in regenerative medicine.
Company Info
Upcoming Milestones & Key Dates
Nasdaq Form 10-Q cure-plan submission deadline (60-day window from May 27, 2026 notice)
Expected Q2 2026 financial results and operational update
Clinical Development Pipeline
Cenplacel-L
Target: Placental-derived cellular biomaterialCYNK-001
Target: Allogeneic placental-derived natural killer (NK) cell therapyCYCART-19
Target: Allogeneic placental-derived CAR-TRecent News
No recent news updates available for this company.
Leadership Team
Robert J. Hariri, M.D., Ph.D.
Chairman, Chief Executive Officer and Founder
Careers & Job Openings